Description
在我们的最新播客中，我们将深入探讨一项突破性研究，该研究发现铁剂配方Ferric Carboxymaltose（FCM）与低磷血症（HPP）有显著关联。这项系统性综述揭示了FCM相关的HPP是一种重要的药物不良反应，常见症状包括全身无力、疲劳、骨痛和肌肉痛，甚至导致骨软化和骨折。研究结果显示，与其他静脉铁制剂相比，FCM相关的HPP发生率要高得多。尽管FDA批准的FCM标签在2023年有所更新，但研究呼吁需要更强有力的HPP预防建议，以保护患者安全。这不仅对医疗专业人员至关重要，也对所有关注药物安全和有效性的听众都具有吸引力。不要错过这一集，了解如何通过监测血清磷酸盐水平来预防和管理这一严重问题。
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare
The method of invention, AI's new clock speed and why capital markets are confused
05 Dec 2025
Azeem Azhar's Exponential View
Meta Stock Surges on Plans for Metaverse Cuts
05 Dec 2025
Bloomberg Tech